MedTrace Logo

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-04-24

No results posted yet for this study

Summary

This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations. Study 1 involved all four arms with 37 people. The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV.

Conditions

  • Healthy Aging

Interventions

DIETARY_SUPPLEMENT

NAD+ (nicotinamide adenine dinucleotide) IV

NAD+ enables cells to generate cellular energy from the food that one eats

DIETARY_SUPPLEMENT

Niagen® (nicotinamide riboside) IV

NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.

DIETARY_SUPPLEMENT

Niagen® (nicotinamide riboside) oral

NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.

OTHER

Placebo

These individuals received a saline IV

Sponsors & Collaborators

  • Nutraceuticals Research Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-13
Primary Completion
2024-03-08
Completion
2024-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06382688 on ClinicalTrials.gov